Skip to content

City Therapeutics Stock

CTYNASDAQ

City Therapeutics Inc., HealthcareISIN US1787821081

$18.35▲ $1.71 (+10.3%)Closing price of 19 Nov 2026

58Score 58 out of 100, Neutral

Turn on early warning

Price and Trend

39 / 100

Price history

−27% in one year

The chart shows daily closes over 13 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.

Long-term trend

Below the 200-day line: the price is 21% below it.

Trend change

Since November 2026 the 50-day line has been below the 200-day line; the trend has turned down.

Momentum

Normal: the price is neither overheated nor sold off (RSI 43).

Distance to the high

The price is 28% below its 52-week high. Largest decline in 13 years: 52% (August 2016 to March 2020).

Chart figures for advanced users
SMA 50$22.32
Average price of the last 50 trading days, shows the short-term trend.
SMA 200$23.34
Average price of the last 200 trading days, shows the long-term trend.
RSI (14)43
Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
MACDabove the signal line
Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
Support$12.50
The lowest closing price of the last twelve months.
Resistance$25.65
The highest closing price of the last twelve months.
Market cap
$979.67M
Div. yield
no dividend
no data
Fair value
no data

Snapshot

Computed from the data by fixed rules, no AI

  • City Therapeutics Inc. belongs to the Biotechnology industry (United States) and, with a market value of $979.67M, is number 185 of 277 companies in its industry on MEQIRI.
  • In fiscal 2019 it reported revenue of $8.16B (down 4% year on year) and earnings of $1.83B (up 9.7%).
  • MEQIRI Score 58 out of 100 (Neutral): rank 281 of 686 in Healthcare, median 53.

In Plain Words

The numbers on this page in plain words, written by an AI

Strengths

  • Consistently ProfitableProfit in all 10 fiscal years from 2010 to 2019.Fundamentals 91
  • High MarginNet margin 22.4% over the last 12 months, Biotechnology median −80.8%.Profitability 82
  • Earnings Turn into CashFree cash flow 121% of earnings over the last 12 months.Fundamentals 91

Weaknesses

  • Volatile Share PriceVolatility 68% a year over the last 12 months.Stability 62
58/ 100
MEQIRI Score
Neutral

Its standout strengths are fundamentals and profitability, while growth and momentum hold the score back.

Daily figure as of 20 Nov 2026

How the score is calculated

Score Overview

Score since yesterday from 56 to 58.

Fundamentals are strong, with stable profits and strong cash generation.

Profit consistency100% of years
Cash conversion (free cash flow to earnings, 12 months)121%
ROIC (12 months)13.4%
Positive free cash flow100% of years
How this category is measured

Score History

The full history of up to 20 years comes with MEQIRI Pro.

See plans

Valuation

Valuation Signal

not measured
Price
$18.35
Fair value
not computable
Gap to fair value
no data

No fair value can be calculated for this stock, so the signal follows the valuation grade.

Valuation metrics

no data
no data
Fair value (model)
no data

No fair value can be calculated for this stock from the available figures.

Calculate with your own assumptions

Company Performance

This shows several years of history with an automatic assessment.

Revenue

15 years

In the twelve months to 30 Jun 2020, revenue fell 22.4% on the twelve months before. Revenue has stayed largely stable since 2005.

Margins

15 years
  • Gross margin
  • Operating margin
  • Net margin

In fiscal 2019: gross 70%, operating 35%, net 22%.

Debt & balance sheet

latest quarter
0.46
> 100x
0.73
Cash & equivalents
$5M

The balance sheet is solid, with moderate debt and comfortable interest coverage.

Insiders

Open-market purchases and sales by executives, board members and major holders

All insider purchases

No open-market purchases or sales in the last 6 months.

Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.

Sector Comparison

686 rated companies in Healthcare

Rank 281 of 686
281/ 686
This company
58
Sector median
53

Categories Against the Sector MedianMedian of 686 companies

Profitability82 (median 39)43 above the median
Growth33 (median 54)21 below the median
Fundamentals91 (median 49)42 above the median
Stability62 (median 68)6 below the median
Capital allocation64 (median 41)23 above the median
Technical analysis39 (median 61)22 below the median
Momentum19 (median 64)45 below the median

The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.

Competitors in Biotechnology

The next larger and next smaller companies by market value

ETFs That Hold City Therapeutics

Held by 2 of the 100 largest US ETFs. Shown per index: the ETF with the largest weight.

ETFWeightCostFund size
Vanguard Extended Market ETFVXF0.00%0.05%$30.2B
Vanguard Morningstar Total Stock Market ETFVTI0.00%0.03%$689.3B

Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).

Data Status and Sources

Score
Daily value of 20 Nov 2026, recalculated nightly
Price
Closing price of 19 Nov 2026
Latest annual report
Fiscal year 2019, period end 31 Dec 2019
Source
Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.

Mandatory Disclosures for This Rating

  • ; time horizon around 12 months
  • Rated Neutral, published since 7 Nov 2026 (in the score history since 29 Feb 2020)
  • End-of-day prices, metrics cached for up to 24 hours
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.